Head-to-head · free
Regeneron Pharmaceuticals, Inc. vs Rhythm Pharmaceuticals, Inc.
REGN vs RYTM — return on capital, cash generation, margins and balance sheet side by side.
REGN
5 / 7
measures where REGN leads
RYTM
2 / 7
measures where RYTM leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | REGN · FY2025 | RYTM · FY2025 |
|---|---|---|
| Revenue | $14.3B | $189.8M |
| Net income | $4.5B | (196.5M) |
| Revenue growth (yearly, multi-year) | -2.8% | 56.5% |
| Free cash flow | — | (116.6M) |
| Free cash flow margin | — | -61.5% |
| Net cash / (debt) | — | — |
| ROIC | 9.3% | — |
| Return on equity | 14.9% | -251.1% |
| Gross margin | 85.4% | 89.7% |
| Operating margin | 25.8% | -101.2% |
| Net debt / EBITDA | -0.27x | 0.28x |
Figures are as reported by each company; latest fiscal year shown.
Where Regeneron Pharmaceuticals, Inc.'s cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Rhythm Pharmaceuticals, Inc.'s cash went (FY2025)
- Capital spending
- $953000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free